A round up of all the latest nanotechnology, nanomaterials, nanomedicine, nanocoatings, graphene and regulatory developments from 1-10 October 2017. Most content is industry related with additional information on interesting research.
This service is only available to Nanotech Magazine Subscribers.
QUANTUM DOTS NEWS
Fighting superbugs with Quantum Dots
In a recent statement, the World Health Organisation (WHO) said that too few antibiotics are in the pipeline to tackle the global crisis of drug resistance, which is responsible for the rise of almost untreatable infections around the world.
Researchers from the University of Colorado Boulder have are using quantum dots to produce chemicals that render bacteria more vulnerable to antibiotics. In the study, antibiotics spiked with quantum dots fought off bacteria as effectively as 1,000 times as much antibiotic alone. http://advances.sciencemag.org/content/3/10/e1701776
CARBON NANOTUBES NEWS
UK company launches carbon nanotubes bike chain product
Muc-Off has released a specially treated carbon nanotubes Shimano Dura-Ace chain that it says offers reduced friction in race conditions and distances. The Nanotube Chain, or NTC for short, is the culmination of over 10 years’ worth of research and development into drivetrain optimisation. https://muc-off.com/blogs/news/muc-off-launches-new-nanotube-chain
REGULATORY AND POLICY NEWS
JRC publisheds nanomaterials framework
The European Commission (EC) Joint Research Center (JRC) has published a Science for Policy report entitled NANoREG framework for the safety assessment of nanomaterials. The report was developed within the NANoREG project, “A common European approach to the regulatory testing of nanomaterials.”
NANOMEDICINE NEWS
Nanomedicine company announces clinical trial for nanoparticle cancer therapy
NanOlogy LLC, a clinical-stage pharmaceutical development company, has announced enrollment of the first patient in a Phase 2 clinical trial of intraperitoneally (IP) administered NanoPac®(nanoparticle paclitaxel) sterile suspension in patients with ovarian cancer. Part of a broad nanoparticle technology platformdeveloped by the company, NanoPac will be evaluated for safety and efficacy after IP instillation of NanoPac at the end of cytoreductive (debulking) surgery.
CorNeat Vision Unveils a Revolutionary Artificial Cornea
CorNeat Vision, an Israeli ophthalmic medical devices startup, has completed the design and development stage of its revolutionary cornea implant (CorNeat KPro / Keratoprosthesis), an associated implantation tool and dedicated manufacturing process. Following solution validation in NZW rabbits, the company is currently initiating formal biocompatibility and safety tests toward first implantation in Humans by mid-2018. The CorNeat KPro implant is a patent-pending synthetic cornea that utilizes advanced cell technology to integrate artificial optics within resident ocular tissue. The CorNeat KPro is produced using nanoscale chemical engineering that stimulates cellular growth. www.corneat.com/product-animation.
